Fig. 3

Increased anti-apoptotic effects of PPARβ/δ-primed MSC on endothelial cells. a After 24 h of MSC pharmacological preconditioning using PPARβ/δ agonist, cells were co-cultured in classical culture medium (CM) using transwells (upper chamber) with EA.hy296 (lower chamber) previously exposed to 350 µM of H₂O₂ in minimal medium (serum deprivation) during 4 h. At the end of the protocol, specific DNA fragmentation was quantified in EA.hy926 cells and values were compared with those obtained for co-cultures with naive MSC or MSC pre-treated with PPARβ/δ antagonists (GSK0660). b Scatter dot plot and bars were presented for specific DNA fragmentation quantified in EA/hy926 at the end of the protocols. Data (mean ± SD for each group of treatment) were normalized by values obtained with EA.hy926 (not challenged by H₂O₂) and compared among groups performed using Kruskal–Wallis with the Dunn’s post hoc test for multiple comparison. On the top of each bar, P values were noted for the comparison first vs EA.hy926/H₂O₂ and second vs MSC. P values vs EA.hy026/H₂O₂ were noted ns for p > 0.999 (naïve MSC), ** for p = 0.0061 (MSC/0.1 µM GW0742), ns for p = 0.0994 (MSC/1 µM GW0742), ns for p = 0.8650 (MSC/0.1 µM GSK0660) and ns for p > 0.999 (MSC/ 1 µM GSK0660). Significance compared to naïve MSC was noted * for p = 0.0347 (MSC/0.1 µM GW0742), ns for p = 0.3957 (for MSC/1 µM GW0742) and ns for p > 0.999 (MSC/GSK0660 at both doses)